329941-92-6Relevant academic research and scientific papers
One-pot Unsymmetrical Ketone Synthesis Employing a Pyrrole-Bearing Formal Carbonyl Dication Linchpin Reagent
Heller, Stephen T.,Newton, James N.,Fu, Tingting,Sarpong, Richmond
supporting information, p. 9839 - 9843 (2015/08/19)
A one-pot procedure for the synthesis of unsymmetrical ketones utilizing a pyrrole-bearing carbonyl linchpin reagent (carbonyl linchpin N,O-dimethylhydroxylamine pyrrole; CLAmP) is reported. In contrast to other carbonyl dielectrophile equivalents, CLAmP enables the synthesis of ketones from a variety of organolithium and Grignard reagents. The electrophilic nature of CLAmP enables the addition of less reactive as well as thermally unstable nucleophiles. CLAmP was designed to form kinetically stable tetrahedral intermediates upon the addition of organometallic nucleophiles. Evidence for the existence of persistent tetrahedral intermediates was obtained through in situ IR studies.
Practical synthesis of a benzophenone-based NNRT inhibitor of HIV-1
Wang, Xiao-Jun,Zhang, Li,Sun, Xiufeng,Lee, Heewon,Krishnamurthy, Dhileepkumar,O'Meara, Jeff A.,Landry, Serge,Yoakim, Christiane,Simoneau, Bruno,Yee, Nathan K.,Senanayake, Chris H.
experimental part, p. 561 - 566 (2012/07/03)
A convergent synthesis of NNRTI 1 is described. The key step involves a direct coupling of acid chloride 4 with Grignard reagent 11 in the presence of bis[2-(N,N-dimethylamino)ethyl] ether that moderates the reactivity of the Grignard reagent to give benzophenone 7. An efficient 2-step process for the preparation of 2-fluoro-3-methyl-4-aminobenzoic acid (3) is also described.
BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE
-
Page/Page column 7; 18, (2010/11/08)
The present invention includes benzophenone compounds (I) which are useful in the treatment of HIV infections.
Novel Benzophenones as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1
Chan, Joseph H.,Freeman, George A.,Tidwell, Jeffrey H.,Romines, Karen R.,Schaller, Lee T.,Cowan, Jill R.,Gonzales, Steve S.,Lowell, Gina S.,Andrews III,Reynolds, David J.,St. Clair, Marty,Hazen, Richard J.,Ferris, Rob G.,Creech, Katrina L.,Roberts, Grace B.,Short, Steven A.,Weaver, Kurt,Koszalka, George W.,Boone, Lawrence R.
, p. 1175 - 1182 (2007/10/03)
GW4511, GW4751, and GW3011 showed IC50 values ≤2 nM against wild type HIV-1 and 10 nM against 16 mutants. They were particularly potent against NNRTI-resistant viruses containing Y181C-, K103N-, and K103N-based double mutations, which account for a significant proportion of the clinical failure of the three currently marketed NNRTIs. The antiviral data together with the favorable pharmacokinetic data of GW4511 suggested that these benzophenones possess attributes of a new NNRTI drug candidate.
